# Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia

> **NCT04659863** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 13 (actual)

## Conditions studied

- Familial Hypercholesterolemia - Homozygous

## Interventions

- **DRUG:** Inclisiran
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04659863
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-16
- **Primary completion:** 2023-10-30
- **Final completion:** 2024-11-18
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04659863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04659863, "Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04659863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*